# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-01-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashworth-Banks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of home blood pressure readings, the repeat urine test and the kidney ultrasound, with the nephrology consultation. **S**

## History of present illness

Mrs. Wells returns two weeks after her first visit with her home blood pressure log and the outside report she obtained: two years ago another clinic measured her creatinine at 1.05 mg/dL and reported an eGFR of 64 as normal. That report used an older equation that raised the estimate for Black patients; recalculated with the race-free CKD-EPI 2021 equation it is 59, already reduced, and no urine albumin test was done then. Her home readings over seven days average 150/88. She stopped naproxen at the first visit and uses acetaminophen for her knees, which works. Her ankles still swell a little by evening and she is still tired in the afternoons. She had her kidney ultrasound this morning and saw Dr. Lindqvist-Moore of nephrology afterwards. She asked to see each calculation and was given copies. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 150/88 over seven days |
| Earlier result | Creatinine 1.05 two years ago, reported with a race-adjusted eGFR of 64; race-free eGFR 59 |
| Naproxen | Stopped; acetaminophen instead |
| Symptoms | Tiredness and evening ankle swelling, unchanged |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired in the afternoons; no fever or weight loss |
| Cardiovascular | Positive | Mild ankle swelling by evening; no chest pain or breathlessness lying flat |
| Genitourinary | Negative | No blood in the urine, foamy urine, or burning |
| Musculoskeletal | Positive | Knee aching, controlled with acetaminophen |
| Integumentary | Negative | No rash or itching |

5 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee aching (no more than 3,000 mg a day), in place of naproxen **S**
- Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 154/90 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 70 kg; BMI 28.4 kg/m². All vital signs are synthetic.

Urine albumin-to-creatinine ratio: 228 mg/g (high). All results are synthetic.

## Change since baseline

- Urine albumin-to-creatinine ratio: 240 mg/g (high) at baseline, 228 mg/g (high) at this visit **S**

## Immunizations given today

- High-dose influenza vaccine, this season **S**
- Pneumococcal conjugate vaccine PCV20 **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 154/90 (average of two), pulse 76; weight 70.0 kg |
| Cardiovascular | Regular rhythm; no murmur or rub; trace ankle swelling |
| Respiratory | Clear |
| Skin | No rash |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3b A2** (N18.32). Confirmed and staged. Race-free eGFR 40 by creatinine and 38 by creatinine with cystatin C, with the earlier value of 59 two years ago showing the disease has been present for at least that long and has fallen by about 10 a year, which is rapid. The older race-adjusted equation would read today's creatinine as 44 and the earlier one as a normal 64; the race-free result recognizes her disease earlier, as the NKF-ASN Task Force intended. Urine albumin-to-creatinine ratio 228 mg/g on repeat (240 at intake): A2. Urinalysis from the first visit: 1+ protein, no blood, bland sediment. No monoclonal protein; free light chain ratio normal. Hepatitis B surface antigen, hepatitis C antibody and HIV negative; hepatitis B surface antibody negative. Ultrasound today: kidneys 9.6 and 9.4 cm, both echogenic with thin cortex, no obstruction or stones. Kidney failure risk about 7% at 5 years and 2% at 2 years. Dr. Lindqvist-Moore judges hypertensive kidney disease most likely, with APOL1-associated disease possible. **S**
   - Losartan 50 mg daily; potassium and creatinine in two weeks.
   - Dapagliflozin to follow once potassium and creatinine are stable.
   - Kidney education session and a dietitian session.
   - APOL1 testing offered after counseling; she chose to defer it.
2. **Hypertension with chronic kidney disease** (I12.9). Home average 150/88 with clinic 154/90: stage 2 hypertension confirmed. Intake ECG showed left ventricular hypertrophy by voltage, consistent with longstanding high blood pressure. **S**
   - Losartan as above; goal below 130/80, and a systolic below 120 if tolerated.
   - Home readings the week before each visit.
3. **Anemia of chronic kidney disease** (D63.1). Hemoglobin 11.2 g/dL with ferritin 168 ng/mL and transferrin saturation 24%: iron replete; mild anemia from kidney disease, likely part of her tiredness. No treatment needed at this level. **S**
   - Hemoglobin again in three months.
4. **Vitamin D deficiency with a mildly raised PTH** (E55.9). 25-hydroxyvitamin D 17 ng/mL and PTH 84 pg/mL, with normal calcium and phosphate: correct the vitamin D first. **S**
   - Vitamin D3 1,000 units daily; PTH and vitamin D in three months.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Standardized office blood pressure (five minutes' rest, validated cuff, average of two readings) | Every visit | Completed today | 154/90 |
| Self-management | Home blood pressure readings | Seven days to confirm; then the week before each visit while medicines change | Completed today | Seven-day average 150/88 confirms hypertension |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; three to six months after a treatment change; then about twice a year at G3b A2 | Completed today | 228 mg/g, confirming the intake result of 240 (A2) |
| Laboratory | Creatinine with cystatin C (eGFRcr-cys) | When decisions depend on accuracy, as at diagnosis and referral | Up to date | Done at intake: eGFR 40 by creatinine, 38 with cystatin C; both race-free |
| Laboratory | Urinalysis with microscopy | At diagnosis and with any change | Up to date | Intake sample: 1+ protein, no blood, bland sediment |
| Imaging | Kidney ultrasound | Once, at diagnosis of chronic kidney disease of uncertain cause | Completed today | Small echogenic kidneys; no obstruction or stones |
| Laboratory | Monoclonal protein screen and hepatitis B, hepatitis C and HIV tests | Once, for chronic kidney disease of uncertain cause in an older adult | Up to date | Drawn at intake: no monoclonal protein, normal free light chain ratio; hepatitis B surface antigen, hepatitis C antibody and HIV negative; not immune to hepatitis B |
| Survey | Kidney failure risk equation, 2- and 5-year | At diagnosis and yearly at G3 to G5; before referral decisions | Completed today | About 7% at 5 years and 2% at 2 years (eGFR 38, albumin-to-creatinine ratio 240 mg/g, age 68, female) |
| Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Two to four weeks after starting or increasing an ARB or SGLT2 inhibitor; then with each eGFR check (about twice a year at G3b A2) | Ordered | Losartan started today; check in two weeks |
| Laboratory | Hemoglobin | At least yearly at G3; recheck in three months when mildly low | Up to date | 11.2 g/dL at intake; iron studies adequate |
| Laboratory | Calcium, phosphate, intact PTH and 25-hydroxyvitamin D | Baseline at G3; then every 6 to 12 months; vitamin D and PTH three months after starting replacement | Up to date | At intake: calcium 9.2, phosphate 3.8 mg/dL; PTH 84 pg/mL; vitamin D 17 ng/mL; vitamin D3 started today |
| Laboratory | Lipid panel | Once at diagnosis; statin for adults 50 or older with eGFR below 60 without routine repeat testing | Up to date | LDL 136 mg/dL at intake; atorvastatin 20 mg started today, without a routine repeat |
| Medication safety | Medication review: NSAIDs, contrast, dose adjustment, sick-day rules | Every visit | Completed today | Naproxen stopped and acetaminophen used instead; sick-day rules for losartan explained in writing |
| Self-management | Lifestyle: sodium below 2 g a day, activity, plant-rich diet | Every visit | Completed today | Dietitian session booked; sodium and protein targets discussed |
| Medication safety | Vaccines for kidney disease (influenza, pneumococcal, hepatitis B, COVID-19) | Review yearly; hepatitis B series if not immune | Completed today | High-dose influenza, PCV20 and hepatitis B dose 1 given after she agreed |
| Referral | Nephrology | When 5-year kidney failure risk is 3 to 5% or more, eGFR falls quickly, or the cause is unclear | Completed today | Seen by Dr. Lindqvist-Moore today; review in three months |

## Goal progress

- Blood pressure below 130/80 mmHg in the clinic and at home within two months of starting treatment, and lower if tolerated. In progress; target 2026-03-03. **S**
- Urine albumin-to-creatinine ratio lower by at least 30% at the three-month check on treatment. In progress; target 2026-03-03. **S**
- No NSAIDs or other avoidable kidney harms; every medicine checked against her kidney function. In progress; target 2026-03-03. **S**
- An informed decision about APOL1 genetic testing, made by her after counseling. Outcome by 2026-01-20: Counseled at the consultation; she chose to defer the test and may ask for it at any time. **S**
- She understands her stage, her risk and the kidney replacement options, and her wishes are recorded, long before any decision is needed. In progress; target 2026-02-17. **S**

## Medication changes

- Started: Losartan 50 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating **S**
- Started: Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Started: Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet daily **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (J Am Soc Nephrol 2021)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), New England Journal of Medicine (Inker LA, et al.)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, anemia and depression monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Potassium and creatinine in two weeks. Kidney education session and dietitian session in the next month. Call for dizziness, swelling of the lips or tongue (call 911), or vomiting or diarrhea that stops her eating and drinking (hold losartan that day). **S**
- Next scheduled visit 2026-02-03: two weeks after starting losartan: potassium, creatinine and blood pressure, and the decision about dapagliflozin. **S**
